Litigation Details for SHIRE LLC v. COREPHARMA, LLC (D.N.J. 2014)

« Back to Dashboard

SHIRE LLC v. COREPHARMA, LLC (D.N.J. 2014)

Docket		Date Filed	2014-09-12
Court	District Court, D. New Jersey	Date Terminated	2016-01-07
Cause	35:145 Patent Infringement	Assigned To	William J. Martini
Jury Demand	None	Referred To	Mark Falk
Parties	COREPHARMA, LLC
Patents	6,322,819; 6,605,300; RE41,148; RE42,096
Attorneys	CYNTHIA STENCEL BETZ
Firms	McCarter and English, LLP
Link to Docket	External link to docket

Details for SHIRE LLC v. COREPHARMA, LLC (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-12				External link to document

Shire LLC v. CorePharma LLC, 2:14-cv-05694: Litigation Summary and Patent Analysis

Last updated: November 3, 2026

Shire LLC sued CorePharma LLC in the U.S. District Court for the District of New Jersey after CorePharma filed an abbreviated new drug application seeking approval for a generic version of Vyvanse, whose active ingredient is lisdexamfetamine dimesylate. The case was an ANDA patent action involving Vyvanse composition and method-of-use patents. The matter ended without a publicly reported trial judgment determining patent validity or infringement. The docket reflects resolution by agreement and dismissal rather than a litigated merits decision.

What was Shire v. CorePharma about?

The case concerned CorePharma’s Paragraph IV certification against patents listed for Vyvanse. CorePharma’s ANDA sought approval to market generic lisdexamfetamine capsules before expiration of Shire’s listed patent rights.

Item	Detail
Case	Shire LLC v. CorePharma LLC
Court	U.S. District Court for the District of New Jersey
Civil action	2:14-cv-05694
Plaintiff	Shire LLC
Defendant	CorePharma LLC
Product	Vyvanse, lisdexamfetamine dimesylate
Regulatory pathway	ANDA under Hatch-Waxman
Dispute type	Paragraph IV patent litigation
Primary market	ADHD treatment
Procedural result	Resolved without a reported merits judgment

Vyvanse is a prodrug of dextroamphetamine. Its design converts to active amphetamine after enzymatic processing in the body. Shire’s patent strategy relied on both the lisdexamfetamine compound itself and treatment methods involving the product.

What patents protected Vyvanse in the CorePharma case?

The principal patents associated with the Vyvanse ANDA disputes included U.S. Patent Nos. 7,105,486 and 8,318,800. The asserted patent set in a particular case depended on the ANDA notice and Shire’s complaint.

Patent	General subject matter	Relevance to Vyvanse
U.S. 7,105,486	Amphetamine prodrugs, including lisdexamfetamine-related compounds	Core composition and prodrug protection
U.S. 8,318,800	Methods of treating ADHD and related dosing or administration approaches	Method-of-use protection

U.S. Patent No. 7,105,486

Patent 7,105,486 covered amphetamine prodrug technology. Its commercial importance came from claims directed to lisdexamfetamine or closely related compound structures and pharmaceutical uses.

The patent had a standard statutory term tied to its earliest effective nonprovisional filing date, subject to any patent-term adjustment or extension. Its listed protection was generally understood to run into 2023, with pediatric exclusivity potentially affecting the practical FDA approval date for certain generic products.

U.S. Patent No. 8,318,800

Patent 8,318,800 covered methods of treating ADHD using lisdexamfetamine-related therapy. Method-of-use patents can create a narrower litigation path than compound patents because an ANDA applicant may attempt a section viii statement that omits a patented indication.

The commercial effect depended on the precise claim scope, the labeling proposed in CorePharma’s ANDA, and whether the generic label would induce infringement of the claimed treatment methods.

When did Shire file the lawsuit?

Shire filed the action in 2014 after receiving CorePharma’s Paragraph IV notice. The lawsuit triggered the Hatch-Waxman 30-month stay, which generally prevents FDA approval of the challenged ANDA for up to 30 months unless the court resolves the case earlier or orders otherwise. The stay mechanism is governed by 21 U.S.C. § 355(j)(5)(B)(iii).

The filing date placed the dispute in the period when Vyvanse remained protected by a high-value composition patent and follow-on method patents. Shire therefore had substantial commercial leverage even though CorePharma could challenge the patents without waiting for expiration.

What was CorePharma’s likely patent challenge?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. In the Vyvanse litigation context, the principal challenge theories would have included:

1. Invalidity based on anticipation or obviousness.
2. Noninfringement based on the structure, formulation, or labeling of the ANDA product.
3. Lack of infringement of method claims because of the proposed label or physician-directed use.
4. Potential limits on the scope of claims covering lisdexamfetamine and related prodrugs.

The compound patent presented the largest barrier because a generic product containing the same active ingredient would face direct infringement risk if the asserted claims covered the marketed drug substance. Method-of-use patents could be addressed through label carving only if the omitted indication and resulting label avoided induced-infringement exposure.

Did the court decide whether Shire’s patents were valid?

No reported final merits decision in this action established that the asserted patents were valid and infringed, or invalid and not infringed. The case ended without a published trial verdict or final written opinion resolving the core patent issues.

That distinction matters. The litigation outcome did not create a broadly applicable invalidity ruling against the Vyvanse patent estate. It also did not produce a binding infringement precedent that would independently determine the outcome of later generic challenges.

How did the litigation end?

The case was resolved through a negotiated disposition, followed by dismissal. Public docket materials do not indicate a full trial adjudicating the asserted claims.

The publicly visible result is therefore procedural rather than substantive:

Issue	Publicly reported result
Claim construction	No widely reported dispositive claim-construction ruling
Patent validity	No final reported invalidity judgment
Infringement	No final reported infringement verdict
Settlement	Case resolved by agreement
Dismissal	Action dismissed after resolution
Generic launch date	Not established by the public docket alone

Hatch-Waxman settlements frequently contain confidential commercial terms. The public docket may show dismissal while withholding the launch date, payment provisions, authorized-generic arrangements, or restrictions on future challenges.

What was the Orange Book status of Vyvanse?

Vyvanse was listed in the FDA’s Orange Book with patent information associated with its active ingredient and approved uses. The Orange Book entries provided the statutory basis for Shire’s patent-enforcement action after CorePharma’s Paragraph IV notice.[1]

The relevant regulatory concepts were:

• The reference listed drug was Vyvanse.
• CorePharma relied on an ANDA rather than submitting a full new drug application.
• CorePharma’s Paragraph IV certification created a private right of action for Shire.
• Shire’s timely lawsuit activated the 30-month stay.
• FDA approval remained subject to the litigation and statutory exclusivity framework.

Orange Book listing does not establish patent validity. It identifies patents that the NDA holder or sponsor submitted for the listed drug under FDA regulations.

When did Vyvanse lose exclusivity?

Vyvanse’s practical exclusivity was layered rather than controlled by one date.

Protection layer	Approximate timing or effect
New chemical entity exclusivity	Expired before the 2014 CorePharma case
Compound patent protection	Extended into 2023
Method-of-use patent protection	Extended beyond the core compound patent for certain claims
Pediatric exclusivity	Could add six months to eligible regulatory protections
Generic approvals	Began appearing after the principal patent barrier ended

The central commercial patent barrier was the compound patent, which was generally associated with expiration in 2023. Follow-on method patents could still affect labeling, approval timing, and litigation risk after compound-patent expiration.

The first wave of generic lisdexamfetamine approvals occurred in 2023. FDA approval of a generic product, however, does not establish that every formulation, dosage form, manufacturing process, or use is free from patent risk.

What generic entry risks existed for CorePharma?

CorePharma faced several distinct entry risks.

Compound infringement risk

A generic capsule containing lisdexamfetamine would likely implicate claims directed to the active compound if those claims covered the product as made, sold, or used. This was the most direct risk.

Method-of-use infringement risk

If the proposed labeling instructed treatment for an indication covered by Shire’s method claims, Shire could pursue induced-infringement theories. A narrow label or section viii carve-out could reduce that risk but would not necessarily eliminate exposure arising from prescribing practices.

Regulatory timing risk

The 30-month stay delayed FDA approval unless the litigation was resolved earlier. A settlement could establish a negotiated entry date that was earlier than unrestrained patent expiration but later than the date CorePharma would have preferred.

Manufacturing risk

Lisdexamfetamine manufacture requires control of the active pharmaceutical ingredient, conversion chemistry, impurity profile, polymorphic or solid-state characteristics where relevant, and pharmaceutical equivalence. A generic applicant could avoid one patent claim while still facing process, formulation, or product-by-process issues.

Commercial launch risk

Vyvanse had a large installed patient base and strong brand recognition. An early generic launch could generate significant volume, but multiple ANDA approvals would compress prices. A delayed launch could reduce the value of CorePharma’s approval because other generic manufacturers might enter simultaneously.

How strong was Shire’s Vyvanse patent estate?

The estate was commercially strong during the 2014 litigation period because it combined:

• A compound patent directed to the core prodrug technology.
• Method-of-use patents directed to ADHD treatment.
• FDA Orange Book listing.
• A commercially successful reference product.
• The ability to obtain a 30-month stay after a timely Paragraph IV suit.

Its main vulnerability was patent-term concentration. Once the principal compound patent expired, multiple generic manufacturers could rely on the same approved active ingredient. Method patents had narrower practical value because they could be challenged through noninfringement theories, label carving, or arguments that ordinary prescribing did not create the required induced infringement.

The absence of a reported final validity judgment leaves the strength assessment based on claim scope, prosecution history, settlement behavior, and subsequent market entry rather than a judicial finding.

Were biosimilar issues relevant?

No. Vyvanse is a small-molecule drug, not a biologic. The relevant pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act.

The competitive risks were generic-drug risks:

• Paragraph IV challenges.
• Abbreviated approval.
• Therapeutic substitution.
• Formulary pressure.
• Multiple-source price erosion.

Which companies challenged or competed with Vyvanse?

The Vyvanse market attracted multiple generic applicants after the main patent barriers approached expiration. Public FDA approval records identify generic lisdexamfetamine products from several manufacturers, including Teva, Sun Pharmaceutical, Apotex, Hikma, and others depending on dosage form and approval timing.[2]

CorePharma’s 2014 case should therefore be viewed as one dispute within a larger ANDA challenge cycle. A settlement with one applicant did not eliminate the broader competitive threat. It instead addressed that applicant’s product and the rights asserted against it.

What licensing or settlement deal did Shire disclose?

The public case record does not provide a complete set of commercial settlement terms. No broad, publicly reported license agreement appears to have converted CorePharma into an early, unrestricted competitor before the principal Vyvanse patent barrier expired.

The absence of public terms prevents a reliable calculation of:

• Any payment from Shire to CorePharma.
• Any authorized-generic arrangement.
• The precise negotiated launch date.
• Restrictions on future patent challenges.
• Supply or manufacturing rights.

The procedural dismissal confirms resolution of the lawsuit, not the full economic structure of the agreement.

What was the revenue exposure?

Vyvanse was one of Shire’s major commercial products and generated multibillion-dollar annual sales near the end of its branded lifecycle. Takeda’s later financial reporting continued to identify Vyvanse as a material product, although reported sales declined after generic competition began.[3]

The CorePharma litigation therefore protected a substantial revenue stream. The value of the case depended on the difference between:

1. Continued branded sales during patent protection.
2. A negotiated generic entry date.
3. The number of competing ANDA applicants.
4. The speed of post-expiration price erosion.
5. Whether Shire could support an authorized-generic strategy.

What is the current litigation significance of the case?

The case has limited precedential value because it did not produce a reported merits decision. Its principal significance is commercial and procedural:

• It shows how Shire enforced Vyvanse patent rights against an early ANDA filer.
• It confirms the importance of the 2014 Paragraph IV challenge cycle.
• It illustrates the value of composition patents before generic entry.
• It shows why method-of-use patents remained relevant after the compound patent approached expiration.
• It demonstrates that settlement records may reveal little about the actual launch economics.

Key Takeaways

• Shire sued CorePharma over a Paragraph IV ANDA for generic lisdexamfetamine, the active ingredient in Vyvanse.
• The dispute arose in the District of New Jersey under Civil Action No. 2:14-cv-05694.
• The relevant Vyvanse patent estate included U.S. Patent Nos. 7,105,486 and 8,318,800.
• The case ended by negotiated resolution and dismissal, without a reported final judgment on patent validity or infringement.
• The principal compound-patent barrier extended into 2023, while method-of-use protection could extend beyond that date for particular claims.
• The dispute did not involve biosimilars. It was a conventional small-molecule Hatch-Waxman ANDA case.
• The public docket does not establish the complete settlement terms or a definitive CorePharma launch date.
• Generic lisdexamfetamine competition expanded after 2023, creating substantial revenue and pricing exposure for the Vyvanse franchise.

FAQs About Shire LLC v. CorePharma

Did CorePharma win the Vyvanse patent case?

The public record does not show a merits victory for either side. The case ended through agreement and dismissal rather than a reported decision holding the asserted patents invalid or not infringed.

Was U.S. Patent No. 7,105,486 the main Vyvanse patent?

Yes. Patent 7,105,486 was the principal composition patent associated with lisdexamfetamine and represented the most direct barrier to a generic product containing the same active ingredient.

Could CorePharma launch generic Vyvanse before 2023?

Only under the terms of its settlement or if it prevailed in litigation. The public record does not disclose a confirmed early launch date for CorePharma.

Did the case establish that Vyvanse patents were valid?

No. Because the case did not produce a reported final validity ruling, it did not establish broad judicial validation of the Vyvanse patent estate.

Is generic lisdexamfetamine a biosimilar?

No. Lisdexamfetamine is a small-molecule drug. Generic versions are approved through the ANDA pathway, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

2. U.S. Food and Drug Administration. (2023–2024). Drugs@FDA: FDA-approved drugs, lisdexamfetamine dimesylate. FDA.

3. Takeda Pharmaceutical Company Limited. (2024). Annual report and financial results for the fiscal year ended March 31, 2024. Takeda.

4. Shire LLC v. CorePharma LLC, No. 2:14-cv-05694, U.S. District Court for the District of New Jersey, docket materials.

5. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,105,486: Amphetamine prodrugs. USPTO.

6. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,318,800: Methods of treating attention deficit hyperactivity disorder. USPTO.